Neurodegenerative disorders are primarily characterized by neuron loss. The most common
neurodegenerative disorders include Alzheimer's and Parkinson's disease. Although there …

The blood brain barrier (BBB) presents a formidable challenge to the delivery of drugs into
the brain. Several strategies aim to overcome this obstacle and promote efficient and …

Abstract Development of drug‐delivery systems that selectively target neoplastic cells has
been a major goal of nanomedicine. One major strategy for achieving this milestone is to …

Peptide–and protein–nanoparticle conjugates have emerged as powerful tools for
biomedical applications, enabling the treatment, diagnosis, and prevention of disease. In …

Obtaining efficient drug delivery to the brain remains the biggest challenge for the
development of therapeutics to treat diseases of the central nervous system. The main …

Due to the ability of the blood–brain barrier (BBB) to prevent the entry of drugs into the brain,
it is a challenge to treat central nervous system disorders pharmacologically. The …

Simple Summary The advancement of nanotechnology over the last three decades has
given new hope to cancer management. The first FDA-approved nanomedicine (DOXIL) was …

Alzheimer's disease (AD) is one of the biggest human health threats due to increases in
aging of the global population. Unfortunately, drugs for treating AD have been largely …

Cell-penetrating peptides (CPPs), also known as protein translocation domains, membrane
translocating sequences or Trojan peptides, are small molecules of 6 to 30 amino acid …

Drug delivery to the brain is hampered by the presence of the blood-brain barrier, which
excludes most molecules from freely diffusing into the brain, and tightly regulates the active …